ClinicalTrials.gg
TerminatedNCT04965818Updated Sep 19, 2024

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

A Phase 1 interventional study of Futibatinib and Binimetinib in Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer and KRAS Gene Mutation, sponsored by Taiho Oncology, Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Why this study was terminated
Strategic decision by sponsor.

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Otsuka Holdings Co., Ltd..

Enrollment
9th of 11
38 · median 128
Started
2021
with 2 others
Phase 1
4 of 13
1 open now
Registered
7th of 13
by date

Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd., this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2021, is one of 4 in phase 1, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Non-Small-Cell Lung by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.

Read the detailed description

This is an open-label, nonrandomized, uncontrolled Phase 1b/2 study to determine the recommended phase 2 dose (RP2D) of futibatinib in combination with binimetinib and to explore the preliminary antitumor activity of futibatinib in combination with binimetinib in patients with advanced KRASmt tumors.

The study will consist of two parts:

  • Part 1: Dose-Escalation part to determine the RP2D and dosing schedule of futibatinib in combination with binimetinib in patients with advanced cancer disease
  • Part 2: Dose-Expansion part to evaluate the preliminary antitumor activity of futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC

Patients will receive study treatment until progressive disease or any other discontinuation or withdrawal criterion is met.

No patients were enrolled in Phase 2 as the Sponsor decided to not proceed with the dose expansion Phase 2 part of the TAS-120-204 study.

03

Conditions studied

  • Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
  • Non-Small Cell Lung Cancer
  • KRAS Gene Mutation

Keywords

  • Futibatinib
  • Binimetinib
  • MEKi
  • FGFR
  • FGFRi
  • TAS-120
  • KRASmt
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed advanced cancer of any tumor type (Part 1) or NSCLC with a confirmed KRAS mutation as determined by local results (Part 2)
  • Appropriate candidate for experimental therapy
  • For patients in Part 2 only: Patient has radiographically per 1.1 criteria.
  • (ECOG) performance status 0 or 1.
  • Adequate cardiac function ( (LVEF) ≥50% )
  • Adequate organ function
  • Must have tumor tissue specimen available (optional for patients in Part 1)

Exclusion criteria

Exclusion Criteria:

  • History or current evidence of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues
  • Current evidence or history of corneal or retinal disorder as confirmed by ophthalmologic examination.
  • Known untreated central nervous system (CNS) or history of uncontrolled seizures.
  • Significant gastrointestinal disorder(s) that could interfere with absorption of futibatinib/binimetinib
  • Patients who have neuromuscular disorders that are associated with elevated creatinine kinase (CK)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Futibitanib in combination with binimetinib

    Dose escalation: Futibitanib in combination with binimetinib in patients with advanced cancer disease. Dose expansion: Futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC

    Drug: Futibatinib and Binimetinib

Interventions

  • DrugFutibatinib and Binimetinib

    Drug pages: Futibatinib · Binimetinib

    Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle

06

What researchers measure

Primary outcomes

  1. Recommended Phase 2 Dose (RP2D) in Part 1

    Determine RP2D of futibatinib in combination with binimetinib based on Dose Limiting Toxicities

    Time frame: 12 months

  2. Objective Response Rate (ORR) in Part 2

    proportion of patients who have achieved a PR or complete response (CR) according to RECIST 1.1.

    Time frame: approximately 24 months

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum plasma concentration (Cmax) of futibatinib, binimetinib, and AR00426032

    Plasma concentrations of futibatinib, binimetinib, and AR00426032

    Time frame: approximately 24 months

  2. PK: Area under the plasma concentration-time curve (AUC) of futibatinib, binimetinib, and AR00426032

    Plasma concentrations of futibatinib, binimetinib, and AR00426032

    Time frame: approximately 24 months

  3. PK: Time to reach maximum plasma concentration (Tmax) of futibatinib, binimetinib, and AR00426032

    Plasma concentrations of futibatinib, binimetinib, and AR00426032

    Time frame: approximately 24 months

  4. PK: Terminal elimination half-life (T1/2) of futibatinib, binimetinib, and AR00426032

    Plasma concentrations of futibatinib, binimetinib, and AR00426032

    Time frame: approximately 24 months

  5. PK: Minimum plasma concentration before administration (Cmin) of futibatinib, binimetinib, and AR00426032

    Plasma concentrations of futibatinib, binimetinib, and AR00426032

    Time frame: approximately 24 months

  6. PK: Accumulation ratio of Cmax and AUC (R) of futibatinib, binimetinib, and AR00426032

    Plasma concentrations of futibatinib, binimetinib, and AR00426032

    Time frame: approximately 24 months

  7. Duration of response (DOR)

    DOR is defined as the length of time between first response and the date of objectively documented progression of disease or death

    Time frame: approximately 24 months

  8. Progression-free survival (PFS)

    PFS is defined as the time from date of first dose to objectively documented progression of disease or death

    Time frame: approximately 24 months

  9. Disease control rate (DCR) at 24 months

    DCR is defined as the percentage of patients who have achieved a CR, PR, or SD.

    Time frame: approximately 24 months

  10. Number of patients with treatment-emergent adverse events as assessed by CTCAE v5.0

    Evaluate safety and tolerability of futibatinib in combination with binimetinib based on treatment-emergent adverse events per CTCAE v5.0(including serious adverse events),clinical laboratory parameters, ECGs, and vital signs

    Time frame: Approximately 24 months

07

Study locations

3 sites
  • University of California Los Angeles UCLA Cancer
    Santa Monica, California 90404, United States
  • Community Cancer Center North
    Indianapolis, Indiana 46250, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jun 2023, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2021
First posted
Jul 16, 2021
StartActual
Sep 20, 2021
Primary completionActual
Jun 11, 2023
CompletionActual
Sep 21, 2023
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04965818
Responsible party
Sponsor
First posted
Jul 16, 2021
Start date
Sep 20, 2021
Primary completion
Jun 11, 2023
Completion
Sep 21, 2023
Last update
Sep 19, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Futibatinib · Binimetinib

Start the discussion